Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

(2019) Panagiotis A Konstantinopoulos et al.   LANCET ONCOLOGY

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations

(2019) Catherine H. Marshall et al.   EUROPEAN UROLOGY

Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial.

(2019) Anup Kasi et al.   JOURNAL OF CLINICAL ONCOLOGY

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

(2019) Kathleen N Moore et al.   LANCET ONCOLOGY

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer

(2019) Xuan Jiang et al.   Cancer Management and Research

Tumour lineage shapes BRCA-mediated phenotypes

(2019) Philip Jonsson et al.   NATURE

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

(2019) Talia Golan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial

(2019) Mansoor Raza Mirza et al.   LANCET ONCOLOGY

Predictive factors for prolonged response to olaparib as maintenance therapy in ovarian cancer patients with BRCA mutations.

(2018) Sana Intidhar Labidi-Galy et al.   JOURNAL OF CLINICAL ONCOLOGY

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

793PDPreliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations

(2018) W Abida et al.   ANNALS OF ONCOLOGY

Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients

(2018) V. Rodriguez-Freixinos et al.   GYNECOLOGIC ONCOLOGY

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors

(2018) Isabella Faraoni et al.   Cancers

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2

(2017) Amit M. Oza et al.   GYNECOLOGIC ONCOLOGY

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

(2017) Karoline B. Kuchenbaecker et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

(2017) Brian A. Dougherty et al.   Oncotarget

Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors

(2016) Brennan Decker et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Targeted sequencing ofBRCA1andBRCA2across a large unselected breast cancer cohort suggests that one-third of mutations are somatic

(2016) C. Winter et al.   ANNALS OF ONCOLOGY

RECIST 1.1—Update and clarification: From the RECIST committee

(2016) Lawrence H. Schwartz et al.   EUROPEAN JOURNAL OF CANCER

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

(2016) Mansoor R. Mirza et al.   NEW ENGLAND JOURNAL OF MEDICINE

Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy

(2015) Christine S. Walsh   GYNECOLOGIC ONCOLOGY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancers associated withBRCA1andBRCA2mutations other than breast and ovarian

(2014) Jacqueline Mersch et al.   CANCER

Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

(2013) Kathryn P. Pennington et al.   CLINICAL CANCER RESEARCH

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors

(2011) Jonathan J. Shuster   Research Synthesis Methods

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

(2010) Bryan T.J. Hennessy et al.   JOURNAL OF CLINICAL ONCOLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE